Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy

No AccessJournal of UrologyAdult Urology1 Apr 2017Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy Fred Saad, Mathieu Latour, Jean-Baptiste Lattouf, Hugues Widmer, Kevin C. Zorn, Anne-Marie Mes-Masson, Veronique Ouellet, Genevieve Saad, Amol Prakash, Sibgat Choudhury, Gang Han, Pierre Karakiewicz, and Jerome P. Richie Fred SaadFred Saad Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Université de Montréal Endowed Chair in Prostate Cancer, Montreal, Quebec, Canada Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Mathieu LatourMathieu Latour Université de Montréal Endowed Chair in Prostate Cancer, Montreal, Quebec, Canada Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Jean-Baptiste LattoufJean-Baptiste Lattouf Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Hugues WidmerHugues Widmer Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Kevin C. ZornKevin C. Zorn Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Anne-Marie Mes-MassonAnne-Marie Mes-Masson Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Medicine, Université de Montréal, Montreal, Quebec, Canada More articles by this author , Veronique OuelletVeronique Ouellet Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada More articles by this author , Genevieve SaadGenevieve Saad Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada More articles by this author , Amol PrakashAmol Prakash Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author , Sibgat ChoudhurySibgat Choudhury Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author , Gang HanGang Han Metamark Genetics, Inc., Cambridge, Massachusetts Department of Epidemiology and Biostatistics, Texas A&M University, College Station, Texas More articles by this author , Pierre KarakiewiczPierre Karakiewicz Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada More articles by this author , and Jerome P. RichieJerome P. Richie Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.09.116AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Current clinicopathological parameters are insufficient to predict the likelihood of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Such information may help identify patients who would likely benefit from adjuvant radiotherapy rather than active surveillance. A multiplex proteomic assay, previously tested on biopsies and found to be predictive of favorable or unfavorable pathology at radical prostatectomy, was assessed for its predictive value to identify patients at higher risk for biochemical relapse. Materials and Methods: Proteomic assays from core needle biopsies of 288 men who subsequently underwent radical prostatectomy at CHUM (Centre hospitalier de l’Université de Montréal) were evaluated for the prediction of subsequent biochemical recurrence. Results: Of the 288 men, biochemical relapse was observed in 47 (16.3%) and metastases were found in 5 (1.7%). Median followup was 68.5 months. The proteomic assay clearly separated patients into 3 categories, including those at low, intermediate and high risk for biochemical relapse (p = 0.0007). Assay scores predicted biochemical relapse on univariate analysis (HR 1.724, p = 0.0002 per 20% change in score), significantly better than other preoperative prognostic parameters. Additionally, the assay score had a significantly higher p value when combined with clinical National Comprehensive Cancer Network® stage compared to stage alone (HR 1.579, p = 0.0017 per 20% change in score). Conclusions: A protein based assay score derived from diagnostic needle biopsy has strong predictive ability for biochemical relapse after surgery. These results suggest that this assay score can be used at the diagnostic stage to identify patients in whom prostate cancer is potentially more biologically aggressive and active treatment should be considered. References 1 : Cancer statistics, 2015. CA Cancer J Clin2015; 65: 5. Google Scholar 2 Final Update Summary: Prostate Cancer: Screening. Rockville: United States Preventive Services Task Force 2015. Google Scholar 3 : Cancer statistics, 2016. CA Cancer J Clin2016; 66: 7. Google Scholar 4 : Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. BJU Int2008; 101: 5. Google Scholar 5 : Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst2009; 101: 1325. Google Scholar 6 : An update of the Gleason grading system. J Urol2010; 183: 433. Link, Google Scholar 7 : What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol2008; 180: 1330. Link, Google Scholar 8 : Gleason score 6 adenocarcinoma: should it be labeled as cancer?. J Clin Oncol2012; 30: 4294. Google Scholar 9 : Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol2009; 27: 3459. Google Scholar 10 : Overdiagnosis and overtreatment of prostate cancer. Eur Urol2014; 65: 1046. Google Scholar 11 : Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol2002; 20: 557. Google Scholar 12 : Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst2009; 101: 1280. Google Scholar 13 : Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol2012; 62: 382. Google Scholar 14 : Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006; 98: 715. Google Scholar 15 : CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy. Can Urol Assoc J2016; 10: 132. Google Scholar 16 : The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer2011; 117: 5039. Google Scholar 17 : Active surveillance: the Canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr2012; 2012: 234. Google Scholar 18 : Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res2015; 21: 2591. Google Scholar 19 : Testing for improvement in prediction model performance. Stat Med2013; 32: 1467. Google Scholar 20 : Utility of risk models in decision making after radical prostatectomy: lessons from a natural history cohort of intermediate- and high-risk men. Eur Urol2016; 69: 496. Google Scholar © 2017 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2019) Re: The Proteogenomic Landscape of Curable Prostate CancerJournal of Urology, VOL. 202, NO. 4, (664-664), Online publication date: 1-Oct-2019. Volume 197Issue 4April 2017Page: 1034-1040Supplementary Materials Advertisement Copyright & Permissions© 2017 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmscancerbiomarkersneoplasm recurrencebiopsylocalwatchful waitingAcknowledgmentsNathalie Delvoye updated patient clinical data.MetricsAuthor Information Fred Saad Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Université de Montréal Endowed Chair in Prostate Cancer, Montreal, Quebec, Canada Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author Mathieu Latour Université de Montréal Endowed Chair in Prostate Cancer, Montreal, Quebec, Canada Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada More articles by this author Jean-Baptiste Lattouf Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author Hugues Widmer Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author Kevin C. Zorn Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Department of Surgery, Université de Montréal, Montreal, Quebec, Canada More articles by this author Anne-Marie Mes-Masson Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Medicine, Université de Montréal, Montreal, Quebec, Canada More articles by this author Veronique Ouellet Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada More articles by this author Genevieve Saad Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada More articles by this author Amol Prakash Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author Sibgat Choudhury Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author Gang Han Metamark Genetics, Inc., Cambridge, Massachusetts Department of Epidemiology and Biostatistics, Texas A&M University, College Station, Texas More articles by this author Pierre Karakiewicz Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada More articles by this author Jerome P. Richie Metamark Genetics, Inc., Cambridge, Massachusetts More articles by this author Expand All Advertisement PDF downloadLoading ...